Mechanism of Action

Angiogenesis: Physiological process involving growth of new blood vessels from preexisting vessels

Antiangiogenic: substance that inhibits angiogenesis

RTK: receptor tyrosine kinase

Other

MCT: Mast Cell Tumor

HRQL: Health-Related Quality of Life

C-ACTC: Canine-Adapted Common Toxicity Criteria (an adaptation for canines of the National Cancer Institute's Common Toxicity Criteria version 2.0). National Cancer Institute, outlined in the Cancer Therapy Evaluation Program’s Common Toxicity Manual, Version 2.0 (June 1999) adapted for dogs.

Receptors

VEGF: vascular endothelial growth factor

PDGF: platelet-derived growth factor

VEGFR: vascular endothelial growth factor receptor

PDGFR: platelet-derived growth factor receptor

SCF: stem cell factor

c-kit: is a Proto-oncogene. c-kit is the receptor for stem cell factor (SCF)

Growth factor: substances capable of stimulating cellular growth, proliferation and differentiation by binding to specific receptors on the surface of target cells.

Growth factor receptor: cell surface receptor that growth factors bind to

Responses

RECIST: Response Evaluation Criteria in Solid Tumors. A set of published guidelines for defining tumor response

Target lesions: Measurable lesions up to a maximum of three lesions; at least one target lesion had to measure ≥ 20 mm at baseline; a lymph node could qualify as a target lesion. (Zoetisdata on file, study 1963C-60-04-688)

Non-target lesions: All lesions other than the target lesions were identified as non-target lesions and their existence recorded at baseline; measurements were of non-target lesions were not required; a lymph node could qualify as a non-target lesion. (Zoetisdata on file, study 1963C-60-04-688)

Complete Response (CR): disappearance of all target and non-target lesions and the appearance of no new lesions

Objective Response Rate (ORR): defined as complete or partial response

Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions using the smallest sum of the longest diameter recorded since treatment initiated as the reference, progression of nontarget lesions, or appearance of a new lesion(s).

Partial Response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, nonprogression of nontarget lesions, and no new lesion(s).

Stable Disease (SD): non-Partial Response / non-Progressive Disease

Biological Response: Responses defined by stable disease ≥10 weeks, complete response or partial response